
Izun Pharmaceuticals: Biopharmaceutical leader in non-steroidal oral anti-inflammatory periodontal therapies.
Izun Pharmaceuticals, founded with a mission to revolutionize periodontal care, focuses on developing non-steroidal topical oral anti-inflammatory therapies. The company aims to provide superior efficacy and safety compared to current periodontal treatments. Their product portfolio is designed to address significant unmet needs in oral health, offering innovative solutions for patients suffering from periodontal diseases.
Notable figures affiliated with Izun Pharmaceuticals include leading experts in biopharmaceutical research and development. The company has attracted investment from prominent venture capital firms, underscoring its potential in the market. Izun Pharmaceuticals has achieved significant milestones in clinical trials, demonstrating the effectiveness of its therapies. Overall, the company is making a substantial impact on oral healthcare by providing safer and more effective treatment options.

Ziran Biopharmaceutical

Innocrin Pharmaceuticals
innocrinpharma.com

Jazz Pharmaceuticals
jazzpharma.com

Concours Pharmaceuticals

PIN Pharma
pinpharma.com

Forward Therapeutics
forward-tx.com

Sea Pharmaceuticals

Zocere
zocere.com

Attune Pharmaceuticals

iQure Pharma
iqurepharma.com

Zai Lab
zailaboratory.com

Zosano Pharma

Navitor Pharmaceuticals

Oryza Pharmaceuticals
oryzapharma.com

Zurex Pharma
zurexpharma.com
Companies similar to Izun Pharmaceuticals include Ziran Biopharmaceutical, Innocrin Pharmaceuticals, Jazz Pharmaceuticals and Concours Pharmaceuticals.
Izun Pharmaceuticals was founded in 2000.
Izun Pharmaceuticals' headquarters is located in New York City, NY, US.
Izun Pharmaceuticals' most recent funding round was for $1.1M (USD) in November 2014.
As of Nov 13, 2014, Izun Pharmaceuticals has raised a total of $5.2M (USD).
Izun Pharmaceuticals has 33 employees as of Feb 5, 2024.